Literature DB >> 1501292

Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis.

G Sczakiel1, M Oppenländer, K Rittner, M Pawlita.   

Abstract

Replication of human immunodeficiency virus type 1 (HIV-1) was inhibited by stable intracellular expression of antisense RNA in the human T-lymphoid cell line Jurkat. When the viral subregion encoding the HIV-1 activator proteins was targeted, the extent of antisense RNA-mediated inhibition was greater than 97% during the first 2 weeks postinfection. Later in the time course, productive HIV-1 infection broke through at high initial infective doses. However, at initial multiplicities of infection equal to or smaller than 0.1, HIV-1 production was not detectable during the 5 weeks of observation. The results underline the effectiveness of stable intracellular antisense RNA expression in inhibiting HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501292      PMCID: PMC289117     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Ribozymes as potential anti-HIV-1 therapeutic agents.

Authors:  N Sarver; E M Cantin; P S Chang; J A Zaia; P A Ladne; D A Stephens; J J Rossi
Journal:  Science       Date:  1990-03-09       Impact factor: 47.728

Review 2.  Progress toward human gene therapy.

Authors:  T Friedmann
Journal:  Science       Date:  1989-06-16       Impact factor: 47.728

3.  Gene therapy in perspective.

Authors:  D J Weatherall
Journal:  Nature       Date:  1991-01-24       Impact factor: 49.962

4.  A novel immune system against bacteriophage infection using complementary RNA (micRNA).

Authors:  J Coleman; A Hirashima; Y Inokuchi; P J Green; M Inouye
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

5.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients.

Authors:  B Ensoli; G Barillari; S Z Salahuddin; R C Gallo; F Wong-Staal
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

6.  Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme.

Authors:  M Weerasinghe; S E Liem; S Asad; S E Read; S Joshi
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

7.  Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression.

Authors:  B Dropulić; N H Lin; M A Martin; K T Jeang
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.

Authors:  S Y Kim; R Byrn; J Groopman; D Baltimore
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

9.  Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma.

Authors:  U Schneider; H U Schwenk; G Bornkamm
Journal:  Int J Cancer       Date:  1977-05-15       Impact factor: 7.396

10.  Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues.

Authors:  S Agrawal; T Ikeuchi; D Sun; P S Sarin; A Konopka; J Maizel; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  15 in total

1.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication.

Authors:  G Veres; U Junker; J Baker; C Barske; C Kalfoglou; H Ilves; S Escaich; H Kaneshima; E Böhnlein
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

Authors:  M A Biasolo; A Radaelli; L Del Pup; E Franchin; C De Giuli-Morghen; G Palu
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

5.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

6.  In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1.

Authors:  K Rittner; C Burmester; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1993-03-25       Impact factor: 16.971

7.  Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.

Authors:  M Homann; S Tzortzakaki; K Rittner; G Sczakiel; M Tabler
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

8.  Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes.

Authors:  T VandenDriessche; M K Chuah; L Chiang; H K Chang; B Ensoli; R A Morgan
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells.

Authors:  Q Xie; A S Anderson; R W Morgan
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells.

Authors:  J Beck; M Nassal
Journal:  Nucleic Acids Res       Date:  1995-12-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.